归因于大血管或小血管病的卒中患者心房颤动的预测因素:STROKE AF 随机临床试验的预设二次分析
STROKE AF 试验的预设二次分析纳入 242 例植入式心脏监测器(ICM)组患者,旨在识别卒中后新发心房颤动(AF)的预测因素。多变量分析显示,仅充血性心力衰竭(HR 5.06)和左心房扩大(HR 3.32)为显著预测因素;两者兼有或其一者 12 个月 AF 检出率为 23.4%,均无者为 5.0%。
要点
- 在归因于大血管或小血管病的缺血性卒中患者中,充血性心力衰竭和左心房扩大与新发心房颤动检出风险显著增加相关。
- 多变量模型中仅充血性心力衰竭(HR 5.06)和左心房扩大(HR 3.32)为显著预测因素。
- 有充血性心力衰竭和/或左心房扩大者 12 个月 AF 检出率 23.4%,均无者 5.0%(HR 5.1)。
核心结论
- 在归因于大血管或小血管病的缺血性卒中患者中,充血性心力衰竭和左心房扩大与卒中后心房颤动检出风险显著增加相关。
- 作者认为这些患者可能从 ICM 作为二级卒中预防策略的一部分中获益最多。
- 作者指出该研究未针对 AF 的临床预测因素进行把握度计算,因此其他临床特征可能未达到统计学显著性。
研究设计与样本
- STROKE AF 随机临床试验的预设二次分析,该试验于 2016 年 4 月 1 日至 2019 年 7 月 12 日入组患者,主要随访至 2020 年,平均(SD)随访时间 11.0(3.0)个月。
- 患者来自美国 33 个临床研究中心,入组标准为归因于大血管或小血管病的指数卒中,且年龄≥60 岁或 50-59 岁伴至少 1 项额外卒中危险因素。
- 共入组 496 例患者,492 例随机分配至研究组(3 例不符合纳入标准,1 例撤回知情同意);本分析纳入随机分配至 ICM 组的 242 例患者。
主要发现
- 在 242 例 ICM 监测患者中,27 例发生 AF(平均[SD]年龄 66.6[9.3]岁;144 例男性[60.0%];96 例女性[40.0%]);2 例基线数据缺失并提前退出研究。
- 单变量预测因素包括年龄(每增加 1 岁:HR 1.05;95%CI 1.01-1.09;P=.02)、CHA2DS2-VASc 评分(每分:HR 1.54;95%CI 1.15-2.06;P=.004)、慢性阻塞性肺疾病(HR 2.49;95%CI 0.86-7.20;P=.09)、充血性心力衰竭(射血分数保留或降低:HR 6.64;95%CI 2.29-19.24;P<.001)、左心房扩大(HR 3.63;95%CI 1.55-8.47;P=.003)、QRS 时限(HR 1.02;95%CI 1.00-1.04;P=.04)和肾功能不全(HR 3.58;95%CI 1.35-9.46;P=.01)。
- 多变量建模(n=197)中,仅充血性心力衰竭(HR 5.06;95%CI 1.45-17.64;P=.05)和左心房扩大(HR 3.32;95%CI 1.34-8.19;P=.009)仍为 AF 的显著预测因素。
- 12 个月时,有充血性心力衰竭和/或左心房扩大的患者(142 例中 40 例)AF 检出率为 23.4%,均无者为 5.0%(HR 5.1;95%CI 2.0-12.8;P<.001)。
关键数值与推荐
- ICM 设备自动检测长度≥2 分钟的心房颤动发作,发作由专家委员会裁定。
- Cox 回归多变量模型纳入单变量分析中 P<.10 的所有参数。
- AF 检出率使用 Kaplan-Meier 生存估计计算。
临床怎么用
- 作者认为,对于归因于大血管或小血管病的缺血性卒中患者,充血性心力衰竭和左心房扩大与新发心房颤动检出风险显著增加相关,这些患者可能从 ICM 作为二级卒中预防策略的一部分中获益最多。
- 原文未据此给出其他推荐。
局限性
- 作者指出该研究未针对 AF 的临床预测因素进行把握度计算,因此其他临床特征可能未达到统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE AF) trial found that approximately 1 in 8 patients with recent ischemic stroke attributed to large- or small-vessel disease had poststroke atrial fibrillation (AF) detected by an insertable cardiac monitor (ICM) at 12 months. Identifying predictors of AF could be useful when considering an ICM in routine poststroke clinical care. OBJECTIVE: To determine the association between commonly assessed risk factors and poststroke detection of new AF in the STROKE AF cohort monitored by ICM. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified analysis of a randomized (1:1) clinical trial that enrolled patients between April 1, 2016, and July 12, 2019, with primary follow-up through 2020 and mean (SD) duration of 11.0 (3.0) months. Eligible patients were selected from 33 clinical research sites in the US. Patients had an index stroke attributed to large- or small-vessel disease and were 60 years or older or aged 50 to 59 years with at least 1 additional stroke risk factor. A total of 496 patients were enrolled, and 492 were randomly assigned to study groups (3 did not meet inclusion criteria, and 1 withdrew consent). Patients in the ICM group had the index stroke within 10 days before insertion. Data were analyzed from October 8, 2021, to January 28, 2022. INTERVENTIONS: ICM monitoring vs site-specific usual care (short-duration external cardiac monitoring). MAIN OUTCOMES AND MEASURES: The ICM device automatically detects AF episodes 2 or more minutes in length; episodes were adjudicated by an expert committee. Cox regression multivariable modeling included all parameters identified in the univariate analysis having P values <.10. AF detection rates were calculated using Kaplan-Meier survival estimates. RESULTS: The analysis included the 242 participants randomly assigned to the ICM group in the STROKE AF study. Among 242 patients monitored with ICM, 27 developed AF (mean [SD] age, 66.6 [9.3] years; 144 men [60.0%]; 96 [40.0%] women). Two patients had missing baseline data and exited the study early. Univariate predictors of AF detection included age (per 1-year increments: hazard ratio [HR], 1.05; 95% CI, 1.01-1.09; P = .02), CHA2DS2-VASc score (per point: HR, 1.54; 95% CI, 1.15-2.06; P = .004), chronic obstructive pulmonary disease (HR, 2.49; 95% CI, 0.86-7.20; P = .09), congestive heart failure (CHF; with preserved or reduced ejection fraction: HR, 6.64; 95% CI, 2.29-19.24; P < .001), left atrial enlargement (LAE; HR, 3.63; 95% CI, 1.55-8.47; P = .003), QRS duration (HR, 1.02; 95% CI, 1.00-1.04; P = .04), and kidney dysfunction (HR, 3.58; 95% CI, 1.35-9.46; P = .01). In multivariable modeling (n = 197), only CHF (HR, 5.06; 95% CI, 1.45-17.64; P = .05) and LAE (HR, 3.32; 1.34-8.19; P = .009) remained significant predictors of AF. At 12 months, patients with CHF and/or LAE (40 of 142 patients) had an AF detection rate of 23.4% vs 5.0% for patients with neither (HR, 5.1; 95% CI, 2.0-12.8; P < .001). CONCLUSIONS AND RELEVANCE: Among patients with ischemic stroke attributed to large- or small-vessel disease, CHF and LAE were associated with a significantly increased risk of poststroke AF detection. These patients may benefit most from the use of ICMs as part of a secondary stroke prevention strategy. However, the study was not powered for clinical predictors of AF, and therefore, other clinical characteristics may not have reached statistical significance. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02700945.
引用
- Schwamm LH, Kamel H, Granger CB, et al. Predictors of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: A Prespecified Secondary Analysis of the STROKE AF Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 36374508. doi:10.1001/jamaneurol.2022.4038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。